Ryo Yamashita1, Reiko Watanabe2, Ichiro Ito2, Hideo Shinsaka3, Masafumi Nakamura3, Masato Matsuzaki3, Masashi Niwakawa3. 1. Division of Urology, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi, Suntougun, Shizuoka, 411-8777, Japan. r.yamashita@scchr.jp. 2. Division of Pathology, Shizuoka Cancer Center, Shizuoka, Japan. 3. Division of Urology, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi, Suntougun, Shizuoka, 411-8777, Japan.
Abstract
PURPOSE: To determine major risk factors for bladder cancer (BC) recurrence after nephroureterectomy (Nux) by focusing on the pathologic appearances of tumors in upper urinary tract urothelial carcinomas (UUTUCs). METHODS: We performed 147 Nux procedures between November 2002 and September 2015. Forty-eight patients were excluded because of a history of BC (28 patients), previous or concurrent radical cystectomy (9 patients), neoadjuvant chemotherapy (5 patients), and other reasons (6 patients). We classified UUTUCs into three types: renal pelvic, short-length ureteral, and long-length ureteral cancer; the cutoff for categorizing short- versus long-length ureteral cancer was the median tumor length. Univariate and multivariate analyses with Cox regression methods were performed to calculate hazard ratios (HRs) for BC recurrence using nine clinical covariates, including our new pathologic classification. RESULTS: The median follow-up period for the survivors was 60 months (range 1-157 months). Of 99 patients, 36 (36%) had BC recurrence; of these 36 patients, 30 (85%) experienced recurrence within 2 years and 17 (47%) had invasive BC (≥pT1). Statistical analyses demonstrated that pathologic tumor type was the major significant risk factor for BC recurrence. Long-length (>5 cm) ureteral cancer had the highest risk of BC recurrence compared to other tumor types (multivariate HR 2.1; 95% confidence interval 1.03-4.2). CONCLUSIONS: Our simple classification system based on the tumor's pathologic appearance is useful for predicting BC recurrence. Patients with long-length ureteral cancer have a high risk of BC recurrence.
PURPOSE: To determine major risk factors for bladder cancer (BC) recurrence after nephroureterectomy (Nux) by focusing on the pathologic appearances of tumors in upper urinary tract urothelial carcinomas (UUTUCs). METHODS: We performed 147 Nux procedures between November 2002 and September 2015. Forty-eight patients were excluded because of a history of BC (28 patients), previous or concurrent radical cystectomy (9 patients), neoadjuvant chemotherapy (5 patients), and other reasons (6 patients). We classified UUTUCs into three types: renal pelvic, short-length ureteral, and long-length ureteral cancer; the cutoff for categorizing short- versus long-length ureteral cancer was the median tumor length. Univariate and multivariate analyses with Cox regression methods were performed to calculate hazard ratios (HRs) for BC recurrence using nine clinical covariates, including our new pathologic classification. RESULTS: The median follow-up period for the survivors was 60 months (range 1-157 months). Of 99 patients, 36 (36%) had BC recurrence; of these 36 patients, 30 (85%) experienced recurrence within 2 years and 17 (47%) had invasive BC (≥pT1). Statistical analyses demonstrated that pathologic tumor type was the major significant risk factor for BC recurrence. Long-length (>5 cm) ureteral cancer had the highest risk of BC recurrence compared to other tumor types (multivariate HR 2.1; 95% confidence interval 1.03-4.2). CONCLUSIONS: Our simple classification system based on the tumor's pathologic appearance is useful for predicting BC recurrence. Patients with long-length ureteral cancer have a high risk of BC recurrence.
Authors: Andrew K Williams; Wassim Kassouf; Joseph Chin; Ricardo Rendon; Niels Jacobsen; Adrian Fairey; Anil Kapoor; Peter Black; Louis Lacombe; Simon Tanguay; Alan So; Jean-Baptiste Lattouf; David Bell; Yves Fradet; Fred Saad; Ed Matsumoto; Darrel Drachenberg; Ilias Cagiannos; Jonathan I Izawa Journal: Urol Oncol Date: 2013-02-13 Impact factor: 3.498
Authors: Thomas F Chromecki; Eugene K Cha; Harun Fajkovic; Vitaly Margulis; Giacomo Novara; Douglas S Scherr; Yair Lotan; Jay D Raman; Wassim Kassouf; Karim Bensalah; Alon Weizer; Eiji Kikuchi; Marco Roscigno; Mesut Remzi; Kazumasa Matsumoto; Thomas J Walton; Armin Pycha; Vincenzo Ficarra; Pierre I Karakiewicz; Richard Zigeuner; Karl Pummer; Shahrokh F Shariat Journal: Eur Urol Date: 2011-09-28 Impact factor: 20.096
Authors: Thomas Seisen; Benjamin Granger; Pierre Colin; Priscilla Léon; Guillemette Utard; Raphaële Renard-Penna; Eva Compérat; Pierre Mozer; Olivier Cussenot; Shahrokh F Shariat; Morgan Rouprêt Journal: Eur Urol Date: 2014-12-06 Impact factor: 20.096
Authors: Evanguelos Xylinas; Luis Kluth; Niccolo Passoni; Quoc-Dien Trinh; Malte Rieken; Richard K Lee; Harun Fajkovic; Giacomo Novara; Vitaly Margulis; Jay D Raman; Yair Lotan; Morgan Rouprêt; Atiqullah Aziz; Hans-Martin Fritsche; Alon Weizer; Juan I Martinez-Salamanca; Kazumasa Matsumoto; Christian Seitz; Mesut Remzi; Thomas Walton; Pierre I Karakiewicz; Francesco Montorsi; Marc Zerbib; Douglas S Scherr; Shahrokh F Shariat Journal: Eur Urol Date: 2013-09-19 Impact factor: 20.096